ORIC Pharmaceuticals Q4 2021 Earnings Report
Key Takeaways
ORIC Pharmaceuticals discontinued the development of ORIC-101 after interim analyses showed insufficient clinical activity. The company will now focus on advancing its three single agent Phase 1 programs and expects to report initial data in the first half of 2023. With cash and investments of $280.4 million, the company's cash runway is extended into the second half of 2024.
ORIC Pharmaceuticals discontinued development of ORIC-101 due to insufficient clinical activity in Phase 1b studies.
The company will focus on advancing ORIC-533, ORIC-114, and ORIC-944, with initial data expected in 1H 2023.
ORIC-114 Clinical Trial Application was filed in Q4 2021 and cleared by the regulatory authorities of the Republic of Korea in Q1 2022.
Cash runway is expected to extend into the second half of 2024, with cash and investments totaling $280.4 million as of December 31, 2021.
ORIC Pharmaceuticals
ORIC Pharmaceuticals
Forward Guidance
ORIC anticipates initial Phase 1b data from ORIC-533, ORIC-114, and ORIC-944 in the first half of 2023.
Positive Outlook
- ORIC-533: Initial Phase 1b data in 1H 2023
- ORIC-114: Initial Phase 1b data in 1H 2023
- ORIC-944: Initial Phase 1b data in 1H 2023